Research across Systemic Lupus Erythematosus
Related studies from across the Systemic Lupus Erythematosus family.
FGF/FGFR signaling systems provide diverse mechanistic targets across multiple systemic autoimmune rheumatic diseases
New research maps potential targets for several autoimmune diseases
This evidence-informed review synthesizes the role of FGF/FGFR signaling in conditions including Rheumatoid Arthritis, SLE, and SSc-ILD. The…
Researchers are mapping out how specific proteins might help manage conditions like rheumatoid arthritis and lupus by targeting tissue repai…
Genistein shows potential to attenuate inflammation and reduce disease severity in autoimmune conditions
Genistein may help reduce inflammation in several autoimmune diseases
This mini review synthesizes preclinical evidence on genistein for autoimmune diseases including SLE, RA, and type 1 diabetes. Findings sugg…
A review of genistein shows it could lower disease severity and inflammation for people with conditions like lupus and rheumatoid arthritis.
Belimumab linked to higher remission and low disease activity rates in SLE without glucocorticoids
Trial shows belimumab improves remission rates for lupus patients
A post hoc analysis of phase III trials found that belimumab plus standard therapy led to higher rates of DORIS remission and LLDAS attainme…
A new analysis of clinical trials shows that the drug belimumab helps more people with lupus reach specific remission goals compared to a pl…
Deucravacitinib modulates up to 2529 genes and SLE-relevant gene sets including interferon-regulated genes
Trial Shows Deucravacitinib Modulates Gene Activity in Lupus Patients
This post hoc analysis of a Phase 2 trial in 363 patients with systemic lupus erythematosus (SLE) found that deucravacitinib modulated up to…
A Phase 2 trial shows that deucravacitinib may influence specific gene sets and immune cell activity in people with systemic lupus erythemat…
Belimumab plus standard therapy shows numerically greater reductions in IgA, IgM, and anti-dsDNA antibodies
Trial Shows Belimumab May Help Manage Lupus Nephritis Symptoms
This Phase 3 randomized controlled trial of 446 adults with active lupus nephritis found that intravenous belimumab plus standard therapy re…
A Phase 3 trial identifies specific markers that may help predict how patients with lupus nephritis respond to belimumab treatment.
Corticosteroid and cyclophosphamide exposure are associated with higher mortality in Middle Eastern and North African SLE
Specific Medications Linked to Survival Rates in Lupus Patients
This meta-analysis of 3,478 adult patients in the MENA region found an all-cause mortality rate of 9.9% (95% CI: 7.2%-14.0%). While corticos…
New data identifies how specific medications and health conditions impact long-term survival for patients with systemic lupus erythematosus.
Anti-DFS70 antibodies show high specificity but low sensitivity for excluding Systemic Lupus Erythematosus
Anti-DFS70 Antibodies May Help Rule Out Systemic Lupus Erythematoma
This meta-analysis evaluates the diagnostic performance of anti-DFS70 antibodies in patients with Systemic Lupus Erythematoma (SLE). The ana…
A large analysis suggests that specific antibodies could help doctors rule out systemic lupus, though more research is needed to confirm the…
Aerobic and resistance exercise improve fatigue, physical function, and pain in systemic lupus erythematosus
Exercise Eases Fatigue and Pain in Lupus Patients
This meta-analysis of 470 adults with SLE found that aerobic, resistance, or combined exercise leads to small-to-moderate improvements in fa…
A review of 470 lupus patients finds exercise improves fatigue, pain, and mood without worsening disease activity.
Small PNH clones in SLE linked to thrombotic events and hemolysis in case series
Small blood cell issues can impact patients with lupus and PNH
A systematic review of 8 cases found that 37.5% of SLE patients with PNH had thrombotic events and 87.5% had detectable hemolysis. The findi…
A review of cases shows that even small clusters of abnormal cells can cause serious blood complications in people with lupus and PNH.
Dapirolizumab pegol increases BICLA response rate by 14.6% over placebo in moderate-to-severe SLE
Trial shows dapirolizumab pegol improves symptoms for lupus patients
This Phase 3 randomized controlled trial of 321 patients with moderate-to-severe, active SLE found that dapirolizumab pegol added to standar…
A new clinical trial found that dapirolizumab pegol significantly improved disease activity for adults with moderate to severe systemic lupu…
SLE patients have a 2- to 3-fold higher risk of intracerebral hemorrhage compared to non-SLE populations
Lupus Patients Face Higher Risk of Brain Bleeding
This literature review and case report analyze the association between systemic lupus erythematosus (SLE) and intracranial hemorrhage (ICH).…
Patients with systemic lupus erythematosus may face a much higher risk of brain bleeds compared to those without the condition.
Systemic immune-inflammation index and systemic inflammation response index correlate with disease activity in systemic lupus erythematosus
Inflammation markers are higher in lupus patients than in healthy people
This meta-analysis of eleven studies involving individuals with systemic lupus erythematosus and healthy controls examined inflammatory mark…
A new analysis shows inflammation markers are much higher in people with lupus. These markers also track closely with how active the disease…